|
2024
|
Invention
|
Compounds as inhibitors of axl.
Compounds of Formula I that inhibit AXL, and compositions contai... |
|
|
Invention
|
Biomarkers for predicting cancer treatment efficacy. Provided herein are biomarkers useful in the... |
|
|
Invention
|
Cbl-b inhibitors and methods of use thereof.
Disclosed herein are compounds having a structure a... |
|
|
Invention
|
Cbl-b inhibitors and methods of use thereof. Disclosed herein are compounds having a structure ac... |
|
|
Invention
|
Cbl-b inhibitors and methods of use thereof.
Disclosed herein are compounds that are Cbl-b inhib... |
|
|
Invention
|
Cbl-b inhibitors and methods of use thereof. Disclosed herein are compounds that are Cbl-b inhibi... |
|
|
Invention
|
Inhibitors of adenosine 5′-nucleotidase. Compounds that modulate the conversion of AMP to adenosi... |
|
2023
|
Invention
|
Modulators of 5'-nucleotidase, ecto and the use thereof.
Compounds that modulate the conversion ... |
|
|
Invention
|
Processes for preparing azolopyrimidine compounds. Disclosed are processes for preparing azolopyr... |
|
|
Invention
|
Lyophilized formulations of cd73 compounds.
Lyophilized formulations comprising a compound of Fo... |
|
|
Invention
|
Lyophilized formulations of cd73 compounds. Lyophilized formulations comprising a compound of For... |
|
|
Invention
|
Antibodies to tigit.
The present disclosure provides antibodies that specifically bind to TIGIT.... |
|
|
Invention
|
Hpk1 inhibitors and methods of use thereof. Disclosed herein are compounds that are Hematopoietic... |
|
|
Invention
|
Dispersions of etrumadenant. Solid dispersion comprising 20-40 wt% of etrumadenant and 60-80 wt% ... |
|
|
Invention
|
Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha. Compounds that inhibit HI... |
|
|
Invention
|
Inhibitors of hpk1 and methods of use thereof.
Disclosed herein are compounds that are Hematopoi... |
|
|
Invention
|
Inhibitors of hpk1 and methods of use thereof. Disclosed herein are compounds that are Hematopoie... |
|
|
Invention
|
Compounds as inhibitors of axl. Compounds of Formula I that inhibit AXL, and compositions contain... |
|
|
Invention
|
Anti-tigit antibodies and uses of the same. Described herein are treatments and preventions for c... |
|
|
Invention
|
Combination therapy for treating trop-2 expressing cancers. e.g.e.g.e.g., etrumadenant, quemliclu... |
|
|
Invention
|
Combination therapy for treating tumor antigen expressing cancers. The present disclosure relates... |
|
|
Invention
|
Crystalline forms of a cd73 inhibitor and uses thereof.
Crystalline forms of the compound of For... |
|
|
Invention
|
Dosing with an azolopyrimidine compound.
Provided herein are methods of treating a disease, diso... |
|
|
Invention
|
Anti-cd39 antibodies and use thereof. Provided herein are anti-CD39 antibodies that inhibit the e... |
|
2022
|
Invention
|
Inhibitors of hif-2α and methods of use thereof. The present disclosure is directed to compounds ... |
|
|
Invention
|
Inhibitors of hif-2alpha and methods of use thereof. The present disclosure is directed to compou... |
|
|
Invention
|
Process for preparing tetralin compounds. The present disclosure describes processes and intermed... |
|
|
Invention
|
Axl compounds.
Compounds of Formula I that inhibit AXL, and compositions containing the compound... |
|
|
Invention
|
Axl inhibitor compounds.
Compounds of Formula I that inhibit AXL, and compositions containing th... |
|
|
Invention
|
Axl compounds. Compounds of Formula I that inhibit AXL, and compositions containing the compound(... |
|
|
Invention
|
Axl inhibitor compounds. Compounds of Formula I that inhibit AXL, and compositions containing the... |
|
2021
|
Invention
|
Azolopyrimidine for the treatment of cancer-related disorders.
Compound that is an inhibitor of ... |
|
|
P/S
|
Pharmaceutical and biological drugs for the treatment of a variety of human diseases and disorder... |
|
|
Invention
|
Crystalline forms of a cd73 inhibitor and uses thereof. Crystalline forms of the compound of Form... |
|
|
Invention
|
Antibodies to tigit. The present disclosure provides antibodies that specifically bind to TIGIT. ... |
|
|
Invention
|
Oral formulations of cd73 compounds. Oral formulations comprising a compound of Formula (I) and a... |
|
2020
|
Invention
|
Inhibitors of hif-2alpha.
Compounds that inhibit HIF-2α, and compositions containing the compoun... |
|
|
Invention
|
Processes for preparing aminopyrimidine compounds.
Provided herein are improved processes for pr... |
|
|
Invention
|
2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds.
Compounds that inhibit PI3Kγ, and comp... |
|
|
Invention
|
Treatment of cancer utilizing an identified adenosine fingerprint.
The present disclosure provid... |
|
|
Invention
|
Treatment of oncogene-driven cancers.
The present disclosure provides methods of treating a subj... |
|
|
P/S
|
Promoting collaboration within the scientific, research, and medical communities to achieve advan... |
|
2019
|
Invention
|
Solid forms of a cd73 inhibitor and the use thereof. Solid forms of Compound I, which modulates t... |
|
|
Invention
|
Inhibitors of arg1 and/or arg2.
Compounds that are inhibitors of at least one of ARG1 and ARG2, ... |
|
2018
|
P/S
|
Pharmaceutical and/or biological drugs for the treatment of a variety of human diseases and disor... |
|
2017
|
P/S
|
Research and development services in the field of cancer immunotherapy; conducting clinical trial... |
